1-Tert-Butyl 2-Ethyl (2S)-2,3-Dihydro-1H-Pyrrole-1,2-Dicarboxylate

In the industrial asymmetric synthesis of the key intermediate (S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid benzyl ester hydrochloride—a bicyclic lactam required for the ACE inhibitors ramipril and benazepril—the chiral pool approach relies on the diastereoselective hydrogenation of 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate. The substrate is dissolved in anhydrous ethanol (≤0.1% H₂O by Karl Fischer) and charged into a Hastelloy C-22 jacketed stirred reactor equipped with a gas-induction impeller operating at 800 rpm. After the addition of 5 wt% (dry basis) sponge nickel catalyst (Actimet M, grain size 20–40 μm), the vessel is purged with nitrogen and pressurized with hydrogen to 18 bar. The exothermic saturation of the pyrroline ring proceeds at 40–45°C; failure to maintain the temperature below 48°C results in epimerization at the 2-position, generating the (2R)-diastereomer in amounts exceeding 2.5% as measured by chiral SFC (stationary phase Chiralpak IG-3, CO₂/methanol 85/15, 3.0 mL/min). The crude (2S)-pyrrolidine diester is not isolated; instead, after catalyst filtration through a 0.5 μm sintered Hastelloy candle filter, the ethanolic solution is treated with 1.05 eq of benzyl chloroformate at pH 9.5–10.0 (maintained by automatic dosing of 20% aqueous Na₂CO₃) to install the Cbz protecting group. The subsequent thermal cyclization in toluene at reflux (110°C) over 6 hours, catalysed by 0.15 eq of glacial acetic acid, forms the bicyclic lactam, which is converted directly into ramipril benzyl ester through a one-pot alkylation with ethyl 2-bromophenylacetate. Throughout this multi-ton campaign, the residual nickel content in the final intermediate is monitored by ICP-MS per ICH Q3D Guideline for Elemental Impurities, with a strict limit of ≤ 20 ppm for nickel (≤ 2.0 μg/g for parenteral finished product); the ethyl acetate content is controlled to ≤ 5000 ppm per ICH Q3C (R8) Class 3 residual solvent specifications. The whole sequence operates as a telescoped process that reduces isolation steps, yet the batch-to-batch cis/trans ratio of the octahydrocyclopenta[b]pyrrole ring system must remain above 98.5 : 1.5 to meet the European Pharmacopoeia monograph for Ramipril (Ph. Eur. 10.5, monograph 2405).

What process tolerance governs the reduction of the pyrroline ring to a cis-fused bicyclic lactam for Glecaprevir?

The construction of the P2 macrocyclic tert-leucine sulfonamide moiety of the HCV NS3/4A protease inhibitor Glecaprevir (ABT-493) involves a chiral pyrrolidin-2-ylmethanol building block derived from 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate. The manufacturing sequence begins with the chemoselective reduction of the ester function at the 2-position to a primary alcohol without touching the N-Boc carbamate. A 2.0 M solution of sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al, ≥65 wt% in toluene) in tetrahydrofuran (THF, Kf ≤ 100 ppm) is metered into a jacketed glass-lined steel reactor (volume 2000 L) containing the substrate at -10°C under a nitrogen blanket. The addition rate is calibrated to keep the internal temperature below -5°C; excursions beyond 0°C promote over-reduction to the corresponding pyrrolidine amine, which irreversibly forms a carbamate dimer through intermolecular attack on the Boc group, lowering isolated yield by 12–18% and generating a turbidity in the work-up that fouls the plate-and-frame filter press (0.7 μm polypropylene cloth). The stoichiometry is fixed at 1.02 eq of reducing agent relative to the substrate; a 2% excess is necessary to drive the reaction to completion (≥99.8% conversion by GC) without producing detectable amine impurity. After aqueous quench with 15% Rochelle’s salt solution, the resulting (S)-N-Boc-2-hydroxymethylpyrrolidine is silylated with 1.1 eq of tert-butyldimethylsilyl chloride in the presence of imidazole (2.5 eq, DMF solvent, 25°C, 16 hours), then subjected to a directed ortho-lithiation and palladium-catalysed Suzuki-Miyaura cross-coupling with a quinoline-derived boronic ester to install the biaryl axis. The cross-coupling employs Pd(dppf)Cl₂·CH₂Cl₂ at 0.5 mol% loading and potassium phosphate tribasic (2.0 eq) in degassed 4:1 dioxane/water at 85°C. At commercial scale, the critical control point is the enantiomeric purity of the hydroxymethyl intermediate; chiral HPLC (Chiralpak AD-H, heptane/ethanol 95/5, 1.0 mL/min) must confirm ≥99.0% ee before coupling, because residual (2R)-isomer propagates into the final API and fails the specification set in FDA Draft Guidance for ANDA submission—where any single unknown impurity exceeding 0.10% requires qualification per ICH Q3A(R2). The final Glecaprevir molecule is registered under the EU Annex I list (active substance No 1839) and must comply with Ph. Eur. monograph 3041 for assay limits of related substances via gradient UPLC-UV at 225 nm.

Chiral phase-transfer catalyst derivatization without N-Boc cleavage

The direct Grignard addition to the cyclic enamine ester functionality of 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate provides a route to N-Boc-2-alkyl-2-pyrroline esters, which serve as precatalysts after conversion into quaternary ammonium salts for asymmetric alkylation of glycine Schiff bases. In a typical large-scale preparation, the pyrroline substrate is dissolved in anhydrous 2-methyltetrahydrofuran (2-MeTHF, Kf ≤ 50 ppm) and cooled to -15°C in a stainless steel stirred reactor. A freshly prepared solution of 4-chlorophenylmagnesium bromide (1.1 eq, 0.8 M in THF) is added via a dosing ring over 90 minutes while maintaining a nitrogen atmosphere and a jacket temperature of -25°C. The conjugated Michael addition across the C=N double bond occurs with inversion of configuration at the 2-position, affording predominantly the trans-adduct. The regiochemical outcome is highly sensitive to Lewis acid additives; the addition of 0.3 eq of anhydrous cerium(III) chloride (activated by grinding and drying at 150°C/5 mbar for 8 hours) suppresses enolization side-products and raises the diastereomeric ratio from 6:1 to 19:1 (determined by ¹H NMR of the crude mixture, 500 MHz, CDCl₃). After quenching with 10% aqueous ammonium chloride and extractive work-up, the product is purified by fractional distillation under high vacuum (boiling point 142–148°C at 0.05 mbar). The resulting N-Boc-2-(4-chlorophenyl)methylpyrrolidine ester is then deprotected with trifluoroacetic acid : dichloromethane (1:1 v/v, 0°C, 2 hours) and neutralized, furnishing the free amine that is subsequently quaternized with 4,4'-bis(bromomethyl)-1,1'-biphenyl under highly dilute conditions (0.01 M in acetonitrile) to form a spirocyclic bis-quaternary ammonium bromide catalyst. The catalyst loading used in the enantioselective phase-transfer benzylation of N-(diphenylmethylene)glycine tert-butyl ester is typically 5 mol% with 50% aqueous KOH as base in toluene at 0°C; this protocol is compliant with USP Chapter <1041> (Biologics) and ICH Q11 Development and Manufacture of Drug Substances for preliminary catalyst screening, while residual palladium, if carried over from the coupling, is controlled by USP <232>/<233> limits. The final tertiary amine target of this catalytic route appears in synthesis of imetelstat (GRN163L), a telomerase inhibitor.

During the preparation of the all-carbon quaternary centre found in the synthesis of the selective SGLT2 inhibitor tofogliflozin intermediate, 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate is employed as a precursor to a chiral pyrrolidine β-amino acid that acts as a constrained isostere of β-thiophenylalanine. The sequence involves a stereoretentive ozonolysis–reductive amination tandem: the pyrroline substrate (1.0 eq) is dissolved in methanol/dichloromethane (1:1, acidified with 0.05 M sulfuric acid) and treated with ozone (generated from oxygen, 3L/min flow, ozone output 80 g/h, Welsbach T-408 ozone generator) at -70°C until a persistent blue colour denotes complete consumption of the enamine; the ozonide is immediately reduced with dimethyl sulfide (3.0 eq) at -50°C rising to 20°C overnight. The resulting aldehyde is telescoped into a reductive amination with dibenzylamine (1.05 eq) and sodium triacetoxyborohydride (1.4 eq) in 1,2-dichloroethane at pH 5–6 (acetic acid buffer). The dibenzyl-protected (S)-2-(aminomethyl)pyrrolidine-1,2-dicarboxylate diester is hydrolysied selectively at the ethyl ester with lithium hydroxide monohydrate (1.02 eq) in 3:1 THF/water at 0°C over 4 hours, yielding the corresponding 2-carboxylic acid without disturbing the Boc group. The acid is coupled with 2-thiopheneboronic acid via a copper-mediated Chan–Lam protocol to install the thiophenyl group, forming the conformaily constrained β-amino acid scaffold. In the commercial manufacturing of tofogliflozin (API listed in JP 18, monograph T-229), the reductive amination step poses a specific batch-failure mode: residual dimethyl sulfide from the ozonide reduction forms S-methyl dibenzothiocarbamate under the basic hydrolysis conditions, which co-crystallizes with the desired acid and raises the sulfated ash content to >0.1%, exceeding the JP requirement for bulk purity. Stringent vacuum degassing (5–10 mbar, 40°C, 2 hours) is therefore mandated after the ozonolysis step, accompanied by headspace GC-MS verification of dimethyl sulfide levels below 50 ppm. The entire intermediate sequence complies with ICH Q3D for palladium (limit ≤10 ppm in the final drug substance) and meets the Drug Master File (DMF) Type II hold time standards for starting material acceptance within 36 months under nitrogen at 2–8°C.

When enantiomeric excess becomes a moving target during scale-up of azabicyclohexane precursors

Synthesis of the spirocyclic hydantoin core of the orexin receptor antagonist daridorexant (ACT-539313) has been described using a chiral bis-protected pyrrolidine carboxylic acid generated from 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate as the starting chiron. The key transformation involves a bicyclization via an intramolecular reductive coupling catalysed by bis(1,5-cyclooctadiene)nickel(0) / 2,2′-bipyridyl and a trialkyl silane hydride source. In a pilot-plant campaign (150–200 kg scale), the pyrroline ester is combined with 1.3 eq of 3-bromobut-3-en-1-ol mesylate and 2.6 eq of triethylsilane in anhydrous THF at -5°C. Nickel catalyst (5 mol%) is pre-formed ex situ in a glovebox under argon (O₂ <5 ppm) and transferred via a dip-tube into the vigorously stirred solution. Cyclization proceeds with generation of ethylene and requires a back-pressure regulator set at 0.2 bar to vent the gas while preventing moisture ingress; moisture levels exceeding 80 ppm in the headspace result in protodesilylation by-product and a fall in isolated yield from 72% to 48% over multiple production batches. The resultant azabicyclo[3.2.0]heptane scaffold is advanced through a Curtius rearrangement triggered by diphenylphosphoryl azide (DPPA, 1.2 eq) and triethylamine in toluene at 80°C, trapping the isocyanate with benzyl alcohol, to yield a protected diamino alcohol that ultimately forms the daridorexant active ingredient. Crucially, the enantiomeric purity of the initial bicyclic intermediate is a direct function of the chiral purity of the starting diester; a 99.0% ee charge gives a product with 97.6% ee after cyclization, but if the starting (2S)-diester stereopurity drops to 99.5% ee (compliant with the supplier certificate of analysis by chiral HPLC, Waters ACQUITY UPC² with Trefoil CEL1 column, 150 × 3.0 mm, 1.7 μm, CO₂/IPA 88/12, 1.8 mL/min), the product sees an amplified drop to 95.9% ee due to a nonlinear kinetic resolution effect in the nickel cyclisation. This behaviour necessitates in-process control via chiral SFC at 15-min intervals during the addition phase. The daridorexant filing follows Swissmedic GMP compliance and requires elemental impurities to conform to ICH Q3D Option 1 (levels as mcg/day); residual nickel is restricted to ≤6.0 μg/day. The final dosage form is an oral film-coated tablet, and the European public assessment report (EPAR) requires a detailed risk assessment of boronic ester starting materials according to the EMA Guideline on the Limits of Genotoxic Impurities (EMA/CHMP/QWP/251344/2006).

In the preparation of a key spiro-proline building block for the oral proteasome inhibitor ixazomib citrate, 1-tert-butyl 2-ethyl (2S)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate is submitted to a two-directional homologation sequence circumventing the need for protecting group manipulations. The process, executed in a 500 L glass-lined reactor under cGMP intermediate conditions, begins with the addition of 1.0 eq of the diester in tetrahydrofuran to a freshly prepared solution of lithium diisopropylamide (1.15 eq, generated from n-butyllithium and diisopropylamine) at -50°C; alkylation is carried out with 1.2 eq of bromomethyl cyclobutane at -40°C over 30 minutes achieving diastereoselectivity of 97:3 (anti:syn) as measured by ¹³C NMR at 125 MHz. The crude alkylated product is heated to 75°C and treated with 1.5 eq of ethylmagnesium bromide to open the lactam ring and form the corresponding δ-amino-β-keto ester. This keto ester is immediately subjected to a Strecker-type cyclization with ammonium chloride (3.0 eq) and sodium cyanide (1.05 eq) in water/methanol at pH 8.0 to yield the spiro hydantoin core. The terminal isolation involves spray drying (Büchi B-290, inlet temperature 180°C, outlet 90°C) to obtain a free-flowing amorphous powder with a residual methanol content of ≤ 100 ppm quantified by headspace GC-FID according to USP <467>. The final spiro intermediate, after debenzylation and citrate salt formation, becomes ixazomib citrate, which is listed in the FDA Orange Book as an approved generic upon expiration of US Patent 8,791,112. The intermediate compliance requires a heavy metal limit of ≤ 20 ppm per USP <231> Method II (historical) and accelerated stability testing at 40°C/75% RH for 6 months per ICH Q1A(R2). A persistent scale-up challenge is the exothermic nature of the LDA alkylation step: the jacket must switch from cooling brine to liquid nitrogen in less than 20 seconds to prevent a temperature overshoot that generates de-Boc by-product and causes a pressure rise to 4.5 bar in the closed vessel, tripping the relief valve on a production unit with a design pressure set at 5.0 bar.